Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance - Kopetz, S; Hoff, PM; Morris, JS (J Clin Oncol, 2010)